BioDelivery Sciences International, Inc. to Post FY2019 Earnings of ($0.26) Per Share, Cantor Fitzgerald Forecasts (BDSI)

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) – Stock analysts at Cantor Fitzgerald issued their FY2019 EPS estimates for shares of BioDelivery Sciences International in a note issued to investors on Tuesday, April 16th. Cantor Fitzgerald analyst B. Folkes expects that the specialty pharmaceutical company will earn ($0.26) per share for the year. Cantor Fitzgerald currently has a “Buy” rating and a $8.00 target price on the stock.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). BioDelivery Sciences International had a negative return on equity of 79.59% and a negative net margin of 60.87%. The firm had revenue of $18.03 million for the quarter, compared to analyst estimates of $16.15 million.

BDSI has been the topic of several other reports. SunTrust Banks initiated coverage on BioDelivery Sciences International in a research note on Tuesday, March 19th. They set a “buy” rating and a $7.00 price target on the stock. Janney Montgomery Scott reaffirmed a “buy” rating and set a $5.00 price objective on shares of BioDelivery Sciences International in a report on Thursday, January 31st. Zacks Investment Research downgraded BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Friday, January 18th. BidaskClub raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Wednesday, February 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of BioDelivery Sciences International in a report on Friday, March 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $5.79.

Shares of BDSI opened at $4.65 on Friday. BioDelivery Sciences International has a 12-month low of $1.70 and a 12-month high of $5.37. The company has a debt-to-equity ratio of 1.74, a quick ratio of 2.82 and a current ratio of 3.07. The stock has a market cap of $329.93 million, a P/E ratio of -6.37 and a beta of 0.46.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN boosted its position in BioDelivery Sciences International by 121.7% during the third quarter. Wells Fargo & Company MN now owns 118,060 shares of the specialty pharmaceutical company’s stock worth $331,000 after purchasing an additional 64,803 shares in the last quarter. JPMorgan Chase & Co. boosted its position in BioDelivery Sciences International by 35.8% during the third quarter. JPMorgan Chase & Co. now owns 267,874 shares of the specialty pharmaceutical company’s stock worth $750,000 after purchasing an additional 70,633 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in BioDelivery Sciences International during the third quarter worth $255,000. Stonepine Capital Management LLC boosted its position in BioDelivery Sciences International by 190.1% during the third quarter. Stonepine Capital Management LLC now owns 4,311,103 shares of the specialty pharmaceutical company’s stock worth $12,071,000 after purchasing an additional 2,825,101 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in BioDelivery Sciences International by 150.0% during the third quarter. Point72 Asset Management L.P. now owns 1,500,000 shares of the specialty pharmaceutical company’s stock worth $4,200,000 after purchasing an additional 900,000 shares in the last quarter. 57.09% of the stock is currently owned by institutional investors and hedge funds.

In other BioDelivery Sciences International news, Director Healthcare Master Fun Broadfin sold 2,000,000 shares of BioDelivery Sciences International stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $5.00, for a total transaction of $10,000,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Francis E. Odonnell, Jr. sold 23,000 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $5.07, for a total value of $116,610.00. Following the completion of the transaction, the director now directly owns 544,187 shares in the company, valued at $2,759,028.09. The disclosure for this sale can be found here. Insiders have sold 2,048,050 shares of company stock worth $10,241,990 over the last ninety days. Company insiders own 13.26% of the company’s stock.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

See Also: Compound Annual Growth Rate (CAGR)

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.